MassBio Announces New Collaboration with Life Sciences Market Intelligence Firm Evaluate Ltd.
CAMBRIDGE, MA (July 30, 2014) – MassBio members can now save on Evaluate’s industry-leading EvaluatePharma® service, the trusted source for pharmaceutical and biotechnology commercial insights, through a new partnership announced today.
By joining the already robust MassBio Purchasing Consortium, Evaluate has committed to offering MassBio members significant savings on its EvaluatePharma subscription-based service, which includes global R&D and commercial intelligence, consensus forecasts to 2020, financial data and valuation tools, and most recently USA drug price and annual cost per patient.
“MassBio relies on EvaluatePharma for critical insights to analyze the pharmaceutical and biotech industry landscape, trends and deals,” said Robert K. Coughlin, President & CEO of MassBio. “We are pleased to be able to offer this important resource to MassBio members at a discount through this new partnership.”
Evaluate will offer MassBio member substantial savings on EvaluatePharma subscriptions including access to their award-winning EP Vantage news and email alerts, exclusive industry reports, Quick Start needs analysis and EvaluatePharma training.
”Evaluate is proud to join the MassBio Purchasing Consortium. Our recent addition of USA sales, volume and pricing analysis emphasizes our dedication to provide companies, at all stages of maturity, with the insights they need to continue to improve their performance,” said Debbie Paul, CEO Americas of EvaluatePharma USA, Inc.
The MassBio Purchasing Consortium aggregates the purchasing power of MassBio member companies to negotiate contracts with vendors that create significant savings for members. Current contracts include lab supplies and equipment, equipment maintenance, hazardous and biomedical waste removal, packaged and bulk gases, office supplies and furniture, travel management, auto insurance, domestic and international shipping, mobile solutions, and scientific journals.
Contract highlights are available online at www.massbio.org.
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing 650 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.
Established in 1996, Evaluate Ltd. is the leader in high quality life science sector analysis. Evaluate’s team of expert analysts transform life science information into insights so companies can improve their performance. EvaluatePharma delivers exclusive consensus sales forecasts to 2020 and trusted insight into biotech and pharmaceutical commercial performance. EvaluateMedTech sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique clinical trial intelligence expertly curated to efficiently analyze the global clinical trial landscape. An award-winning editorial team, EP Vantage, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends. The Evaluate services enable the life science community to make sound business decisions about value and opportunity.